Fig. 3: Proteins were clustered into expression profiles across our treatment cohort groups: vehicle, 0.1 ⌠M talazoparib, RT3D [MOI of 0.1] or combination (RT3D/talazoparib) and then pathway enrichment analysis was carried out on each cluster.

Three key pathways: RIG-I, NF-∣B and apoptotic proteins (associated with death domains) were found to be enriched in the cluster where highest expression was with combination treatment (RT3D/talazoparib) compared to 0.1 ⌠M talazoparib or RT3D [MOI of 0.1] which showed higher expression than vehicle (A). The proteins expressed in the key pathways are summarised as heatmaps with the RIG-I pathway (B), NF-∣B pathway (C) and apoptotic proteins [associated with death domains] (D). Graphical abstract summarising the relevant proteins involved in the recognition, signalling and execution of RT3D infection and talazoparib treatment following STRING analysis (E). Each protein is represented by a circle divided in four parts: vehicle, 0.1 ⌠M talazoparib, RT3D [MOI of 0.1] or combination (RT3D/talazoparib). These levels are color-coded from green (low expression) to white (identical expression) to red (high expression) and represent their value normalised to vehicle. In addition, cytokines that were analysed by ELISA are summarised (as detailed in Fig. 5B and Supp Fig. 8). RIGI-PARP1 interaction studies are summarised later in the paper (Fig. 6E and Supp Fig. 11E). Source data are provided as a source data file.